Understanding how changes in bone physiology and homeostasis affect immune responses will inform how to retain strong immunity in patients with bone disease and in aged individuals. We previously identified sclerostin (Sost) as a mediator of cell communication between the skeletal and the immune system. Elevated bone mineral density in Sost-knockout (Sost 
Introduction
Sclerostin-antibody therapy (Scl-Ab, romozosumab) has shown great promise for the treatment of osteoporosis, but the possible side effects of Scl-Ab administration and sclerostin depletion outside of the skeletal system are incompletely understood. Our previous work in the global Sost -/-mouse revealed that B lymphocyte development in the bone marrow (BM) was adversely affected, resulting in reduced mature B cell numbers in the BM with high apoptotic activity (1) and our recent work using conditional Sost -/-mice demonstrated a key role for Sost in mesenchymal stem cells on B cell maturation (2) . Despite this reduction in the BM, no differences in B lymphocyte number were observed in the spleen. These results suggested that the obstruction in B cell development in Sost -/-mice was limited to bone marrow B cells, and that any B cells that completely matured then migrated to the spleen to fulfill normal immune functions in the periphery. In our original study, we focused our analyses on mice at peak bone mineral density (12-16 weeks of age), but patients enrolled in Scl-Ab clinical trials span an age range of 55-90 years (3, 4) . To more closely align our investigations with potential clinical outcomes of Scl-Ab administration in older individuals, we compared the effects of sclerostin deficiency on B cell development and the humoral immune response in young and aged mice.
Materials and Methods
Mice. Sost -/-mice have been previously described (1) . Mice of both sexes were used on the C57BL/6 background and housed in sterile, microisolator cages with autoclaved feed and water. The UC Merced IACUC approved all animal work.
Flow cytometric analysis of bone marrow and spleen cells. Procedures for euthanasia, dissection and preparation of femurs, tibias and spleens were performed as previously described (1) . Details on bone marrow cell harvest and antibody staining are described in Supporting Information. 
Results

Sost -/-mice display age-related changes in B cell populations in the bone marrow and spleen
Changes in bone architecture are evident as early as 5 weeks of age in Sost -/-mice (5) . To determine whether Sost -/-mice exhibit an age-dependent functional defect in B lymphocytes, we compared the B cell frequencies and numbers in the BM and spleens of "young" (1-3 months of age) and "aged" (>11 months of age) Sost -/-mice. We found that young Sost -/-mice displayed similar total B cell (B220 + IgM + and CD19 + B220 + ) frequencies and absolute cell counts in the BM to that of age-matched wild-type (WT) controls ( Figure 1A -C and Supp. Figure 1 ). In addition, the frequency of mature B220
high IgM + B cells in the young Sost -/-BM was decreased ( Figure 1G ), but this did not result in a difference in cell number ( Figure 1H ). Aged Sost -/-mice displayed a more dramatic bone mineral density defect, where the bone marrow cavity was almost completely occluded. As expected, total BM cellularity ( Figure 1A) and the frequency of B cells present in the BM were significantly decreased in these mice compared to age-matched controls ( Figure 1A been reported in the murine spleen (6) .
T-cell independent B cell responses are enhanced in young sclerostin-knockout mice
Peripheral B cell responses against T-independent antigens were tested using immunization with NP-Ficoll, a classic multimeric, repeating epitope-bearing T-independent type 2 (T1-2) antigen that simulates an immune response to polysaccharide antigens similar to those found on bacterial cell wall antigens (7, 8) (Figure 2A) . We quantified the NP-specific T-independent immune response in Sost -/-mice by ELISA for NP-specific antibodies of the IgM and IgG3 isotypes in the peripheral blood (9) and compared these responses to age matched controls. Antibody titers in immunized mice were compared to pre-immunization levels, as well as to WT and Sost -/-mice that received injections of phosphate-buffered saline (PBS). Young immunized WT and Sost -/-mice both elicited a strong NP-specific response compared to saline-treated controls ( Figure 2B, 2C ). No differences in the IgM titers were observed in NP-Ficoll immunized young or aged Sost -/-mice compared to controls ( Figure 2B, 2D) . However, the levels of NP-specific IgG3 were significantly higher in the young immunized Sost -/-mice compared to age-matched immunized controls ( Figure 2C ). This IgG3 response was blunted in the aged immunized Figure 2 ).
Discussion
Recent reports on the clinical trials of Scl-Ab aimed at treatment for bone fragility diseases such as osteoporosis demonstrate promising results (3, 4) . However, effects on the immune system have not yet been examined. Our results show that the B cell response to protein antigens is diminished in younger Sost -/-mice, and these data may be relevant to human pediatric patients that receive Scl-Ab for treatment of osteogenesis imperfecta (13) . On the other hand, B cell response to protein antigens was universally weak in both older WT and Sost -/-mice, which might explain why relatively few of the adult patients receiving Scl-Ab mount an immune response to the Scl-Ab (which itself is a protein antigen) (3, 4) . That is, inhibition of the T-dependent antigen response by Scl-Ab may promote the efficacy and effectiveness of Scl-Ab therapy itself. We have not observed differences in the frequencies, numbers and activation capacity of T cells in Sost -/-mice, but further investigation is necessary to reveal if subtle differences exist within T cell subsets within the Sost -/-microenvironment, such as follicular T helper cells (14) , which normally promote co-stimulation of B lymphocytes. Cells of the myeloid lineage can also promote cell responses by conventional B cells (15) , providing an alternative area for experimentation.
Our previous studies demonstrated no effect on Sost deficiency on the in vitro B cell response to the T-independent type 1 (TI-1) antigen lipopolysaccharide (1) . Thus, the enhanced ability of B cells in younger Sost -/-mice to respond to NP-Ficoll in vivo, is intriguing. Responses to T-independent antigens can be mediated by innate-like B cells, such as unconventional B-1 lymphocytes (a fetally-derived cell population that persists during adulthood in the peritoneal cavity and mucosa, and may also develop postnatally in the BM (16, 17) ), and splenic marginal zone B cells (18) . Further investigation is required to determine the mechanisms underlying the enhanced IgG3 response to T-independent antigens in the younger Sost -/-mice, such as a simple decrease in conventional B lymphocytes, and if sclerostin deficiency promotes expansion, activation and/or changes in Fc receptor expression in innate-like B cell subsets (19) . The fact that a weaker IgG3 response to T-independent antigens was observed in older Sost -/-mice compared to age-matched WT controls suggests that there is a role of Sost on innate-like B cells or their microenvironments (20) , and this phenotype is only uncovered after a significant period of time.
In conclusion, we demonstrate that sclerostin deficiency affects the peripheral B lymphocyte immune response to foreign antigens in mice, which could be relevant to the ongoing human clinical trials of Scl-Ab therapies. Our data suggest that B cell responses to both T-independent and T-dependent antigens, such as those found in routinely administered vaccines, be regularly monitored in patients that receive Scl-Ab treatment. 
